JP2019501647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501647A5 JP2019501647A5 JP2018528669A JP2018528669A JP2019501647A5 JP 2019501647 A5 JP2019501647 A5 JP 2019501647A5 JP 2018528669 A JP2018528669 A JP 2018528669A JP 2018528669 A JP2018528669 A JP 2018528669A JP 2019501647 A5 JP2019501647 A5 JP 2019501647A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric receptor
- domain
- variant
- amino acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700010039 chimeric receptor Proteins 0.000 claims 56
- 235000001014 amino acid Nutrition 0.000 claims 25
- 229940024606 amino acid Drugs 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 238000012986 modification Methods 0.000 claims 13
- 230000004048 modification Effects 0.000 claims 13
- 230000011664 signaling Effects 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 102220292761 rs576215366 Human genes 0.000 claims 8
- 108010033276 Peptide Fragments Proteins 0.000 claims 7
- 102000007079 Peptide Fragments Human genes 0.000 claims 7
- 230000000139 costimulatory effect Effects 0.000 claims 7
- 230000001086 cytosolic effect Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 108020001756 ligand binding domains Proteins 0.000 claims 6
- 102220610001 Bestrophin-2_L34A_mutation Human genes 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 102220610000 Bestrophin-2_R31A_mutation Human genes 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102200082944 rs1135071 Human genes 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 102220471762 Proteasome subunit alpha type-7_K28A_mutation Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102200112956 rs104893657 Human genes 0.000 claims 1
- 102200031779 rs3204853 Human genes 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022187652A JP2023022161A (ja) | 2015-12-03 | 2022-11-24 | 修飾キメラ受容体ならびに関連する組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262911P | 2015-12-03 | 2015-12-03 | |
| US62/262,911 | 2015-12-03 | ||
| US201662348130P | 2016-06-09 | 2016-06-09 | |
| US62/348,130 | 2016-06-09 | ||
| PCT/US2016/064861 WO2017096329A1 (en) | 2015-12-03 | 2016-12-02 | Modified chimeric receptors and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022187652A Division JP2023022161A (ja) | 2015-12-03 | 2022-11-24 | 修飾キメラ受容体ならびに関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501647A JP2019501647A (ja) | 2019-01-24 |
| JP2019501647A5 true JP2019501647A5 (https=) | 2020-01-16 |
| JP7184645B2 JP7184645B2 (ja) | 2022-12-06 |
Family
ID=57851322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528669A Active JP7184645B2 (ja) | 2015-12-03 | 2016-12-02 | 修飾キメラ受容体ならびに関連する組成物および方法 |
| JP2022187652A Pending JP2023022161A (ja) | 2015-12-03 | 2022-11-24 | 修飾キメラ受容体ならびに関連する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022187652A Pending JP2023022161A (ja) | 2015-12-03 | 2022-11-24 | 修飾キメラ受容体ならびに関連する組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12139526B2 (https=) |
| EP (2) | EP4212547A1 (https=) |
| JP (2) | JP7184645B2 (https=) |
| CN (2) | CN108884140B (https=) |
| AU (1) | AU2016363025B2 (https=) |
| CA (1) | CA3007262A1 (https=) |
| ES (1) | ES2940607T3 (https=) |
| MA (1) | MA43380A (https=) |
| MX (1) | MX2018006789A (https=) |
| WO (1) | WO2017096329A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3011307T3 (en) | 2012-02-23 | 2025-04-07 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
| SI3132247T1 (sl) | 2014-04-16 | 2021-12-31 | Juno Therapeutics Gmbh | Postopki, kompleti in naprava za povečanje populacije celic |
| CA2946312A1 (en) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| ES2819553T3 (es) | 2014-12-03 | 2021-04-16 | Juno Therapeutics Inc | Métodos y composiciones para terapia celular adoptiva |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| FI3240805T3 (fi) | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| US20180072990A1 (en) * | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| MX2018004875A (es) | 2015-10-22 | 2018-08-01 | Juno Therapeutics Gmbh | Metodos para cultivar celulas y kits y aparatos para ello. |
| AU2016341529B2 (en) | 2015-10-22 | 2023-03-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| PL3368571T3 (pl) | 2015-10-30 | 2023-05-02 | The Regents Of The University Of California | Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania |
| AU2017319702B2 (en) | 2016-09-02 | 2024-11-14 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| WO2018154386A1 (en) * | 2017-02-21 | 2018-08-30 | Eutilex Co., Ltd. | Hla-dr car-t compositions and methods of making and using the same |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| JP7339160B2 (ja) | 2017-04-27 | 2023-09-05 | ジュノ セラピューティクス ゲーエムベーハー | オリゴマー粒子試薬およびその使用方法 |
| CA3070998A1 (en) * | 2017-07-25 | 2019-01-31 | Board Of Regents, The University Of Texas System | Enhanced chimeric antigen receptors and use thereof |
| US10543263B2 (en) * | 2017-10-16 | 2020-01-28 | Lentigen Technology Inc. | Compositions and methods for treating cancer with anti-CD22 immunotherapy |
| US12258580B2 (en) | 2017-11-01 | 2025-03-25 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| MX2020005907A (es) | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| CN112566643A (zh) * | 2018-06-12 | 2021-03-26 | 加利福尼亚大学董事会 | 用于治疗癌症的单链双特异性嵌合抗原受体 |
| US12516099B2 (en) * | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| AU2019317229A1 (en) | 2018-08-10 | 2021-02-18 | Eutilex Co.,Ltd | Chimeric Antigen Receptor that Binds HLA-DR, and CAR-T Cell |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4004030A1 (en) * | 2019-07-24 | 2022-06-01 | Eureka Therapeutics, Inc. | Chimeric antigen receptor t cells and uses thereof |
| CN114502580B (zh) * | 2019-07-30 | 2025-10-17 | 大学健康网络 | Mhc ii类分子及其使用方法 |
| AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
| JP7439279B2 (ja) * | 2020-02-13 | 2024-02-27 | イミュノファーム テクノロジー カンパニー リミテッド | キメラ抗原受容体の最適化 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (https=) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| IL115766A0 (en) | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| AU4705201A (en) | 1999-10-27 | 2001-06-25 | Cel-Sci Corporation | Peptide constructs for treating autoimmune and related diseases |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| CN102764425B (zh) | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
| ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| GB0202399D0 (en) | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040138116A1 (en) | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20070264229A1 (en) | 2004-09-13 | 2007-11-15 | Strominger Jack L | Peptides for Treatment of Autoimmune Disease |
| US20080118532A1 (en) | 2006-06-01 | 2008-05-22 | Atassi M Zouhair | Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| GB0723712D0 (en) | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| ES2660180T3 (es) | 2007-12-07 | 2018-03-21 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| AU2010263272C1 (en) | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| EP2601521B1 (en) | 2010-08-06 | 2018-05-02 | Ludwig-Maximilians-Universität München | Identification of t cell target antigens |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9193997B2 (en) | 2010-12-15 | 2015-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Measuring and monitoring of cell clonality |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| MX2013011363A (es) | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| US20140348861A1 (en) | 2011-05-05 | 2014-11-27 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| WO2013150284A1 (en) | 2012-04-02 | 2013-10-10 | University Of Bristol | Tolerisation- inducing composition |
| EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2015131978A1 (en) | 2014-03-04 | 2015-09-11 | Merck Patent Gmbh | Robust antibody purification |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| MX375379B (es) | 2014-05-29 | 2025-03-06 | Us Health | Receptores de celulas t anti - papilomavirus 16 e7 humano. |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| ES2819553T3 (es) | 2014-12-03 | 2021-04-16 | Juno Therapeutics Inc | Métodos y composiciones para terapia celular adoptiva |
| DK3271382T3 (da) | 2015-03-16 | 2020-05-04 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek |
| CN104910279B (zh) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
| EP3156067A1 (en) | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
| EP4212166A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| MX2019003768A (es) | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| JP2020537515A (ja) | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
-
2016
- 2016-12-02 EP EP22213396.9A patent/EP4212547A1/en not_active Withdrawn
- 2016-12-02 ES ES16829013T patent/ES2940607T3/es active Active
- 2016-12-02 AU AU2016363025A patent/AU2016363025B2/en not_active Ceased
- 2016-12-02 JP JP2018528669A patent/JP7184645B2/ja active Active
- 2016-12-02 CA CA3007262A patent/CA3007262A1/en active Pending
- 2016-12-02 CN CN201680080438.2A patent/CN108884140B/zh active Active
- 2016-12-02 CN CN202211269666.8A patent/CN116041538A/zh active Pending
- 2016-12-02 US US15/780,623 patent/US12139526B2/en active Active
- 2016-12-02 EP EP16829013.8A patent/EP3383892B1/en active Active
- 2016-12-02 WO PCT/US2016/064861 patent/WO2017096329A1/en not_active Ceased
- 2016-12-02 MA MA043380A patent/MA43380A/fr unknown
- 2016-12-02 MX MX2018006789A patent/MX2018006789A/es unknown
-
2022
- 2022-11-24 JP JP2022187652A patent/JP2023022161A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501647A5 (https=) | ||
| JP2019522465A5 (https=) | ||
| JP2018525006A5 (https=) | ||
| CN102906112B (zh) | Trail r2-特异性多聚体支架 | |
| JP2017537919A5 (https=) | ||
| JP2020511949A5 (https=) | ||
| JP2017527272A5 (https=) | ||
| HRP20210498T1 (hr) | De novo vezujuća domena koja sadrži polipeptide i njihova upotreba | |
| JP2025138715A5 (https=) | ||
| JP2019514361A5 (https=) | ||
| JP2023527049A5 (https=) | ||
| JP2018512145A5 (https=) | ||
| RU2017134140A (ru) | Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования | |
| JP2011501951A5 (https=) | ||
| JP2020505034A5 (https=) | ||
| JP2019527537A5 (https=) | ||
| JP2017527310A5 (https=) | ||
| HRP20220865T1 (hr) | T stanični receptori | |
| JP2019521643A5 (https=) | ||
| JP2018515088A5 (https=) | ||
| JP2019530441A5 (https=) | ||
| JP2014524908A5 (https=) | ||
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| FI3665192T3 (fi) | Muunneltuja transferriinireseptoria sitovia polypeptidejä |